The popularity of Sildenafil initially fueled a surge for major pharmaceutical companies, nevertheless recent changes present a murky outlook for shareholders. Off-patent alternatives are eating into earnings, and https://minarywm673574.dgbloggers.com/41605743/sildenafil-and-the-pharmaceutical-industry-a-risky-play